Background
==========

The prevalence of obesity has reached epidemic proportions and is of great public health concern. Its metabolic complications, such as dyslipidemia and type 2 diabetes (T2D), represent a significant cost for the society. Though obesity is often triggered by life style, the importance of genetic predisposition has been clearly demonstrated \[[@B1]\]. Defining gene alleles that are associated with obesity will contribute to our understanding of the underlying mechanisms behind its development and potentially provide therapeutic targets.

Estrogen signalling is implicated in both central, that is regulation of food intake, and peripheral pathways protecting against adiposity. Low estrogen levels following menopause are associated with loss of subcutaneous (sc) and gain of visceral fat \[[@B2]\]. Estrogens signal via the transcription factors estrogen receptors α and β (ESR1, ESR2) \[[@B3]\]. Silencing of the *ESR1*gene in mice renders an obese phenotype \[[@B4]\]. Both *ESR1*and *ESR2*are expressed in the hypothalamus, a brain area known to be involved in the regulation of appetite and satiety \[[@B5]\], whilst adipocytes express mainly *ESR1*\[[@B6]\]. In the brain, *ESR2*has been implicated in mediating the effects of estrogen on food intake \[[@B7]\]. As for peripheral effects of estrogens, hormone replacement therapy (HRT) has been shown to inhibit Epinephrine-stimulated lipolysis in human sc adipose tissue \[[@B8]\]. Estrogen, signalling through ESR1, lowers the lipolytic response in sc fat by increasing the number of antilipolytic α2-adrenoceptors \[[@B9]\].

Human genetic studies support a role for the *ESR*genes in regulation of body weight and certain aspects of the metabolic syndrome. Body mass index (BMI) (LOD 4.6, 4.2 and 2.8), waist circumference (LOD 3.3) and high-density lipoprotein (HDL) cholesterol levels have been linked to the chromosomal region harbouring *ESR1*\[[@B10]-[@B13]\]. Among four investigated *ESR1*polymorphisms, rs2234693 and rs9340799 were associated with waist circumference and rs1801132 with BMI in men, but not women \[[@B14]\]. In another study, *ESR1*rs9340799, but not rs2234693, was associated with waist and BMI in Japanese women but not men \[[@B15]\]. Furthermore, neither rs2234693 nor rs9340799 was associated with obesity in Swedish women \[[@B16]\]. More recently, among 17 investigated *ESR1*polymorphisms, rs6902771, rs2431260 and rs2175898 were associated with BMI in African Americans \[[@B17]\]. Among these same 17 *ESR1*polymorphisms, rs1709183 and rs2431260 were associated with T2D in European Americans and rs1033182 in African Americans \[[@B18]\]. *ESR2*has primarily been investigated in eating disorders. *ESR2*rs928554 and rs4986938, but not rs1256049, have been associated with bulimic behavior \[[@B19]\] and rs1256049, but not rs4986938, with anorexia nervosa \[[@B20]\]. Rosenkrantz et al screened the coding region of *ESR2*in probands of different weight extremes, but identified no mutations associated with the studied phenotypes \[[@B21]\].

We have recently reported that *ESR1*mRNA expression levels in sc adipose tissue and isolated adipocytes from premenopausal women are inversely correlated with BMI \[[@B16]\]. However, whether *ESR1*protects against obesity or is upregulated as a result of low BMI remains to be established. In this report we analyse polymorphisms covering most of the common haplotype variation in the *ESR1*and *ESR2*genes for association with obesity in two large cohorts of Swedish Caucasians. We also investigate if *ESR1*is important for lipid turnover in human adiposity by analysing mRNA levels and gene polymorphisms for association with adipose tissue lipolysis and lipogenesis phenotypes in a third cohort of women., Table [1](#T1){ref-type="table"}. To our knowledge, this represents the first extensive analysis of the impact of variations in the *ESR1*and *ESR2*genes for the development of obesity.

###### 

Sample phenotypic distributions

  Name Phenotype                Sample 1 Obesity   Sample 2 Obesity replication   Sample 3^a^Fat cells                   
  ----------------------------- ------------------ ------------------------------ ---------------------- --------------- -----------------
  Obese                         Women (N = 581)    Men (N = 124)                  Women (N = 689)        Men (N = 148)   Women (N = 216)
  Age (years)                   41 ± 12            45 ± 13                        43 ± 11                45 ± 12         38 ± 10
  BMI (kg/m^2^)                 43 ± 5             45 ± 5                         37 ± 5                 45 ± 5          38 ± 5
  HOMA~IR~                      5.3 ± 5.7          10.5 ± 16.5                    4.5 ± 5.7              8.2 ± 5.5       3.8 ± 2.8
  Pl-cholesterol (mmol/l)       5.2 ± 1.           5.2 ± 1.2                      5.3 ± 1.1              5.2 ± 1.1       5.2 ± 1.1
  Pl-HDL cholesterol (mmol/l)   1.2 ± 0.3          1.0 ± 0.2                      1.3 ± 0.3              1.1 ± 0.3       1.2 ± 0.3
  Pl-triglycerides (mmol/l)     1.7 ± 0.9          2.3 ± 2.3                      1.7 ± 1.0              2.0 ± 1.2       1.6 ± 1.0
                                                                                                                         
  Lean                          Women (N = 338)    Men (N = 64)                   Women (N = 525)        Men (N = 88)    Women (N = 12)
  Age (years)                   50 ± 4             57 ± 8                         39 ± 6                 36 ± 11         33 ± 8
  BMI (kg/m^2^)                 22 ± 2             23 ± 2                         22 ± 3                 23 ± 1          22 ± 2
  HOMA~IR~                      1.3 ± 0.7          1.6 ± 0.8                      1.3 ± 1.0              1.4 ± 0.7       1.4 ± 0.9
  Pl-cholesterol (mmol/l)       5.4 ± 1.0          5.7 ± 1.1                      4.7 ± 0.8              4.9 ± 1.1       4.8 ± 0.7
  Pl-HDL cholesterol (mmol/l)   1.7 ± 0.4          1.4 ± 0.4                      1.6 ± 0.4              1.3 ± 0.5       1.6 ± 0.4
  Pl-triglycerides (mmol/l)     0.9 ± 0.5          1.5 ± 1.0                      0.9 ± 0.5              1.3 ± 1.4       0.8 ± 0.2

Values are mean ± SD

a\) 99 subjects overlap between sample 1 and 3.

Methods
=======

Subjects and clinical evaluation
--------------------------------

Samples 1 and 2 were recruited for the purpose of studying genes underlying susceptibility to obesity, Table [1](#T1){ref-type="table"}. In sample 1, the lean subjects were subjects \> 45 years old and had never reached BMI \> 25 kg/m^2^whereas the obese subjects had BMI \> 30 kg/m^2^at \< 20 years of age or morbid obesity, *i.e.*BMI \> 40 kg/m^2^. These recruitment criteria resulted in more young obese than lean subjects, Table [1](#T1){ref-type="table"}. The aim of selecting subjects with an extreme BMI phenotype in sample 1 was to enrich for a genetic impact on obesity \[[@B22]\]. This was also the purpose of recruiting young obese adults, since early onset of this disorder is believed to have a stronger genetic component due to reduced time of environmental impact \[[@B22]\]. The size of sample 1 provided 90% power to detect an allele with a frequency of 20% among controls and odds ratio (OR) ≥ 1.5 to develop obesity assuming a threshold P value of 0.05 and dominant impact on obesity \[[@B23]\]. 59 subjects in sample 1 were diagnosed with T2D according to self report, but otherwise the subjects were healthy and free of medication according to self-report. 381 subjects in sampe 1 were also included in our previously reported analysis of two *ESR1*SNPs in obesity \[[@B16]\].

Sample 2 had less stringent inclusion criteria for obesity and leanness in comparison with sample 1. Sample 2 comprised healthy non-obese subjects \> 25 years old with BMI \< 25 kg/m^2^and obese individuals with BMI \> 30 kg/m^2^, Table [1](#T1){ref-type="table"}. 197 of the obese subjects in sample 2 had hypertension, 116 T2D, and 50 dyslipidemia according to self report. Differences in recruitment criteria resulted in phenotypic differences between sample 1 and 2, Table [1](#T1){ref-type="table"}. The ratios between men and women were similar among obese and lean in both samples (17--21%).

Sample 3 comprised obese and lean otherwise healthy women recruited with the purpose of studying fat cell function, Table [1](#T1){ref-type="table"}. Lipolysis and lipogenesis were investigated in 204 obese women in sample 3. 204 subjects provide approximately 75% power to detect an allele with a frequency of 20% and R^2^0.04 assuming a threshold P value of 0.05 and dominant impact on adipocyte phenotypes \[[@B23]\]. *ESR1*mRNA levels in adipose tissue were quantified in the 122 women of sample 3 for which RNA was available. 99 women in sample 3 who met the criteria for obesity in sample 1 were included in both samples.

All subjects above were Caucasians and at least second generation Swedish. Obese subjects were recruited from an outpatient center for treatment of obesity or through local advertisement. All lean subjects were recruited through local advertisement. All subjects came to the laboratory in the morning after an overnight fast. A venous blood sample was obtained for extraction of genomic DNA and determination of serum insulin, as well as plasma glucose, triglycerides, total cholesterol, and HDL cholesterol as described \[[@B24],[@B25]\]. Insulin resistance index HOMA~IR~(homeostasis model assessment) was calculated as fasting serum insulin (μU/ml) × fasting plasma glucose (mmol/l)/22.5 \[[@B26]\]. The ethical committee of the Karolinska University Hospital (Southern Campus) approved the study. It was explained in detail to each participant and her/his consent was obtained.

Lipolysis and lipogenesis investigation
---------------------------------------

In the morning after an overnight fast a sc fat biopsy was obtained from the abdominal area by needle biopsy \[[@B27]\]. One part of the adipose tissue pieces was immediately frozen in liquid nitrogen for subsequent RNA analysis. Another piece was digested with collagenase to isolate fat cells and mean fat cell weight was determined \[[@B28]\]. Lipolysis in isolated fat cells was investigated as described \[[@B29],[@B30]\]. Briefly, cell suspensions were incubated in the absence or presence of increasing concentrations of noradrenaline, the non-selective β-adrenoceptor agonist isoprenaline, or the α2-adrenoceptor selective agonist clonidine. At the end of incubation an aliquot of the medium was removed for analysis of glycerol release, which was used as an index of lipolysis.

Lipogenesis was investigated by determining the uptake of radio labeled glucose into lipids as described \[[@B31]\]. Briefly, diluted suspensions of fat cells were incubated in the absence or presence of increasing concentrations of crystalline human insulin (10^-15^--10^-6^mol/l) for 2 h at 37°C. Incubation was terminated by addition of sulphuric acid and radioactivity incorporated into lipids determined.

The concentration (log mol/l) of hormone or agonist causing half maximum effect was determined using logarithmic conversion of each concentration response curve. This value was converted to its negative form (pD~2~), which reflects hormone sensitivity. The maximum effect or responsiveness of hormone or agonist was determined as glycerol release or glucose incorporation into lipids at the maximum effective hormone concentration.

mRNA quantification
-------------------

Total RNA was prepared from adipose tissue and reverse transcribed as described \[[@B32]\]. All qPCR assays were run in triplicates on an ABI 7500 machine (Applied Biosystems, Foster City, CA, USA). A direct comparative method was used for data analysis with *GAPDH*as control gene (User Bulletin \#2, Applied Biosystems). The amplification was repeated twice to confirm results. *ESR1*was amplified by Taqman whereas a SYBRGreen assay was applied for *GAPDH*. Primer/probe sequences were as follows: *ESR1*(F: 5\'-AATATGCCCTTTTGCGATG-3\'; R: 5\'-ACAAAGCAAAGCTGCGACAA-3\'; and Taqman probe: 5\'-CTATTACTGATGTGACTCGGT-3\'), GAPDH (F: 5\'-TGACAACTTTGGTATCGTGGAAGG-3\'; R: 5\'-AGGCAGGGATGATGTTCTGGAGAG-3\').

SNP selection and genotyping
----------------------------

Genotype information for *ESR1*and *ESR2*and regions approximately 10 000 base pairs up- and downstream of these genes were downloaded from HAPMAP in May 2005 \[[@B33]\]. Genotype data for the population of individuals of European ancestry were visualized using Haploview \[[@B34]\]. We initially selected tag-SNPs defining all haplotypes with frequency \> 5% from the block-by-block tags displayed in the HAPLOVIEW \"Haplotypes\" window. However, sometimes these tag-SNPs were exchanged to other SNPs on the same haplotype due to difficulties in designing genotyping assays. In addition, in regions not covered by common haplotypes we aimed to select one common SNP (allele frequency \> 5%) every 5 000 base pair. No non-synonymous SNPs full-filling these criteria were detected in the *ESR*genes. In selecting between different SNPs we prioritized (1) Golden-gate validated assays, and (2) SNPs with high score according to Illumina, which indicate that the designed Illumina genotyping assays are highly likely to work \[[@B35]\]. Besides the HAPMAP SNPs we genotyped the *ESR2*SNPs rs928554 and rs4986938, which previously have been associated with feeding behavior \[[@B19]\].

Samples 1 and 3 were genotyped using the Illumina technology at the SNP technology platform in Uppsala \[[@B36],[@B35]\] except SNPs rs928554 and rs4986938 that were genotyped by RFLP as described \[[@B19]\]. Sample 2 was genotyped using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (SEQUENOM Inc., San Diego, California) as described \[[@B37]\]. Primers can be provided on request. The genotype call rate for all genotyping platforms was ≥ 97% and the accuracy was 99.99% according to duplicate analysis of, on average, 2% of the total genotypes. Hardy-Weinberg equilibrium (HWE) calculations were performed to ensure that each marker was within population equilibrium.

Statistical analyses
--------------------

Association between *ESR1*mRNA levels and lipolysis and lipogenesis measures was assessed by multiple regression with age and BMI as additional independent variables. The Finetti software \[[@B38]\] using Pearson\'s goodness-of-fit Chi^2^was employed to test for allelic association between single SNPs and obesity. ANCOVA with age and BMI as covariates were used to analyze differences in insulin resistance and blood lipid phenotypes between genotypes. HOMA~IR~, Pl-HDL cholesterol, and Pl-triglycerides were ln-transformed before analysis to become normally distributed. For genetic analysis of adipocyte lipolysis and lipogenesis, logarithm transformed phenotypes were used as independent quantitative variables in linear regression models. Genotypes were indicated as character (nominal) with three levels, two different homozygous and heterozygous. There was no association between the adipocyte phenotypes and age or BMI in our sample and these variables were therefore not included in the regression model. Haplotypes were estimated and analyzed with Haploview \[[@B34]\]. LD was calculated as D\'. We used HAPMAP Caucasian data to define haploblock limits. Association between haplotypes and obesity status was evaluated by Chi^2^. Haplotypes with frequency \< 5% and individuals with \> 50% missing genotypes were excluded in the analysis. We performed 10 000 permutations in Haploview to adjust P values to multiple tests.

Results
=======

ESR genotyping results
----------------------

To investigate if *ESR1*and *ESR2*alleles contribute to susceptibility to obesity, polymorphisms covering the common variation in these genes were genotyped in sample 1, Table [2](#T2){ref-type="table"}. For *ESR1*, 6 out of 29 (21%) Illumina genotyping assays failed, which is higher than the expected 10% failure rate. The majority represented Golden-gate validated assays indicating, according to the supplier, that the failure is due to interference between different SNP assays under the employed multiplex conditions. LD between *ESR*gene SNPs is shown in Figure [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, in which haploblock limits according to Caucasian HAPMAP data have been labeled. Genotyped *ESR1*SNPs built 25 haplotypes, Table [3](#T3){ref-type="table"}. These SNPs unambiguously identified 67% (20/30) of the common (\> 5%) haplotypes in the *ESR1*region in HAPMAP, representing 75% of the common haplotype variation in *ESR1*according to HAPMAP data. Remaining ten *ESR1*haplotypes in HAPMAP could in our sample not be separated from another haplotype, that is they were merged into five haplotypes. For *ESR2*, all genotyped assays were called successfully although one SNP, rs7154455, displayed a low genotyping call rate, 83%, Table [2](#T2){ref-type="table"}. Thus there was 100% coverage of the common Caucasian *ESR2*haplotypes in HAPMAP, Figure [2](#F2){ref-type="fig"}. All SNPs were in HWE.

![LD (D\') between *ESR1*SNP and haploblocks according to Caucasian HAPMAP data.](1471-2350-8-73-1){#F1}

![LD (D\') between *ESR2*SNP and haploblocks according to Caucasian HAPMAP data.](1471-2350-8-73-2){#F2}

###### 

Genotyped *ESR1*and *ESR2*SNPs

  Marker                  Gene position   Chromosome position   Alleles   Common allele (%)   Call rate (%)   Chi^2^of HWE
  ----------------------- --------------- --------------------- --------- ------------------- --------------- --------------
  *ESR1*(Chromosome 6)                                                                                        
  rs488133                5\'             152217558             C \> T    68                  98              0.45
  rs532010                5\'             152223032             A \> G    65                  98              0.95
  rs11155813              intron 1        152241549             T \> C    88                  96              0.06
  rs1709182               intron 2        152267471             T \> C    66                  96              0.81
  rs1709183               intron 2        152286110             T \> C    72                  98              0.4
  rs9340835               intron 2        152292045             G \> A    68                  98              0.06
  rs6557170               intron 3        152295218             G \> A    79                  95              0.97
  rs2347867               intron 3        152321964             A \> G    68                  98              0.17
  rs9397456               intron 3        152339266             G \> A    80                  98              0.15
  rs12154178              intron 3        152343194             A \> C    72                  98              0.59
  rs3020317               intron 4        152370855             T \> C    82                  98              0.03
  rs1884051               intron 4        152375393             A \> G    71                  98              0
  rs1884054               intron 4        152383680             A \> C    67                  98              0.47
  rs7754762               intron 4        152403651             T \> A    87                  97              1.61
  rs7757956               intron 4        152409254             T \> A    86                  98              2.69
  rs9340954               intron 4        152412286             T \> G    70                  98              2.89
  rs3020368               intron 5        152463304             C \> T    91                  97              0.05
  rs3778082               intron 6        152479778             G \> A    86                  95              1.76
  rs2982896               intron 6        152491607             C \> T    77                  97              0.01
  rs3020383               intron 7        152508893             G \> C    92                  97              0.28
  rs3778099               intron 7        152510689             T \> C    87                  97              1.18
  rs2813544               3\'             152517696             A \> G    79                  98              0.88
  rs1543403               3\'             152520818             G \> C    52                  96              1.48
  *ESR2*(Chromosome 14)                                                                                       
  rs3020450               5\'             63838055              C \> T    70                  93              6.29^a^
  rs1271572               5\'             63831670              C \> A    54                  98              1.03
  rs1887994               intron 1        63830364              C \> A    89                  97              0.28
  rs7159462               intron 1        63828629              C \> T    92                  97              0.14
  rs1269056               intron 3        63813643              C \> T    56                  97              1.3
  rs7154455               intron 3        63806413              G \> C    64                  83              0.23
  rs1256061               intron 7        63773346              G \> T    50                  97              1.89
  rs1256063               intron 7        63771970              G \> A    91                  94              0.27
  rs4986938               3\'             63769569              G \> A    62                  100             0.56
  rs928554                3\'             63763948              A \> G    56                  100             2.8
  rs1152582               3\'             63762383              C \> G    56                  98              0.71

a\) HWE among controls n.s.

###### 

Association of *ESR1*and *ESR2*haplotypes with obesity

                                                 Cases   Controls               
  ----------------------------------------- ---- ------- ---------- ----- ----- ---------
  *ESR1*                                                                        
  rs488133-rs532010-rs11155813                                                  
  CGT                                       34   449     917        288   508   0.12
  TAT                                       33   455     911        250   546   0.37
  CAT                                       21   285     1081       167   629   0.96
  CAC                                       11   158     1208       82    714   0.36
  rs1709182                                                                     
  T                                         67   925     441        516   282   0.14
  C                                         33   441     925        282   516   0.14
  rs6557170-rs2347867                                                           
  GA                                        68   916     450        549   249   0.40
  AG                                        21   299     1067       165   633   0.52
  GG                                        11   151     1215       84    714   0.68
  rs12154178                                                                    
  A                                         18   976     390        575   223   0.76
  C                                         28   390     976        223   575   0.76
  rs3020317                                                                     
  T                                         82   1116    250        652   146   1.00
  C                                         18   250     1116       146   652   1.00
  rs1884054                                                                     
  A                                         67   920     446        531   267   0.70
  C                                         33   446     920        267   531   0.70
  rs7754762-rs7757956-rs9340954-rs3020368                                       
  TTTC                                      69   947     420        557   239   0.75
  ATGC                                      13   185     1181       99    697   0.47
  TAGT                                      8    113     1253       69    727   0.77
  TAGC                                      5    67      1299       43    753   0.59
  rs3778082-rs2982896                                                           
  GC                                        63   862     502        502   296   0.90
  GT                                        23   310     1054       197   601   0.30
  AC                                        14   192     1172       99    699   0.27
  rs2813544-rs1543403                                                           
  AC                                        48   640     727        396   402   0.21
  AG                                        31   419     948        248   550   0.82
  GG                                        21   301     1065       152   646   0.10
  *ESR2*                                                                        
  rs3020450-rs1271572-rs1887994-rs7159462                                       
  CACC                                      46   639     727        346   452   0.12
  TCCC                                      29   372     994        254   544   0.024\*
  CCAC                                      11   153     1213       79    719   0.33
  CCCT                                      8    116     1251       65    733   0.83
  CCCC                                      6    81      1285       49    749   0.86
  rs1256061-rs1256063                                                           
  TG                                        50   671     689        401   397   0.68
  GG                                        41   547     814        331   467   0.57
  GA                                        10   142     1218       66    732   0.10
  rs4986938-rs928554-rs1152582                                                  
  GGG                                       44   619     747        333   465   0.10
  AAC                                       38   502     864        310   488   0.32
  GAC                                       18   233     1133       149   649   0.35

Analysis of ESR SNPs and haplotypes in obesity
----------------------------------------------

No *ESR1*SNP displayed significant allelic association with obesity, but one SNP, rs2813544, was associated with obesity in analysis of homozygous subjects only, nominal P value 0.05, Table [4](#T4){ref-type="table"}. Two *ESR2*SNPs, rs7154455 and rs3020450, displayed allelic association with obesity in the joint analysis of women and men, nominal P value 0.0003--0.01, Table [4](#T4){ref-type="table"}. In permutation test, the association between rs7154455 and obesity remained significant (P value 0.0022), whereas the result for rs3020450 became borderline significant (P value 0.064). Both SNPs were associated with obesity in women, but not in men. For *ESR2*SNPs rs1152582, rs1271572 and rs1269056, allelic associations with obesity were observed in women, nominal P value 0.03--0.05, but not in joint analysis of women and men, Table [4](#T4){ref-type="table"}. *ESR2*SNP rs4986938 was associated with obesity in men only, nominal P value 0.05. rs7154455 and rs3020450 were genotyped in sample 2 where no association with obesity was observed, Table [4](#T4){ref-type="table"}. Nor was there any association with obesity in analysis of pooled samples 1 and 2 (results not shown). No *ESR*SNP was associated with HOMA~IR~, Pl-cholesterol, Pl-HDL cholesterol, and Pl-triglycerides with P \< 0.0125, and did thus not remain significant after Bonferroni correction for analysis of several SNPs (results not shown).

###### 

Association between *ESR*SNPs and obesity in samples 1 and 2^a^

  Gene       SNP         Controls (n)   Cases (n)   Allele Frequency   Heterozygous   Homozygous   Recessive model   Armitage\'s trend test                                                                                                                                  
  ---------- ----------- -------------- ----------- ------------------ -------------- ------------ ----------------- ------------------------ ------------- --------------------- ------------ --------------------- ------------ --------------------- ------------- ------ -------------
  Sample 1                                                                                                                                                                                                                                                                   
  *ESR1*     rs2813544   10             134         255                33             242          408               0.82 \[0.66--1.02\]      0,08          0.55 \[0.26--1.14\]   0,11         0.48 \[0.24--1.00\]   **0,05**     0.51 \[0.25--1.04\]   0,06          0,79   0,07
             Women       8              114         213                29             194          339               0.83 \[0.66--1.06\]      0,13          0.47 \[0.21--1.06\]   0,06         0.44 \[0.20--0.98\]   **0,04**     0.45 \[0.20--1.00\]   **0,04**      0,79   0,13
             Men         2              20          42                 4              48           69                0.77 \[0.45--1.31\]      0,33          1.20 \[0.20--7.08\]   0,84         0.82 \[0.14--4.68\]   0,82         0.94 \[0.17--5.30\]   0,95          0,78   0,31
  *ESR2*     rs7154455   107            167         47                 273            260          62                0.70 \[0.57--0.85\]      **0,0003**    0.61 \[0.45--0.82\]   **0,001**    0.52 \[0.33--0.80\]   **0,003**    0.59 \[0.44--0.78\]   **0,0002**    0,7    **0,0003**
             Women       84             144         43                 223            219          45                0.63 \[0.51--0.78\]      **0,00003**   0.57 \[0.41--0.80\]   **0,0008**   0.39 \[0.24--0.64\]   **0,0001**   0.53 \[0.39--0.73\]   **0,00007**   0,62   **0,00002**
             Men         23             23          4                  50             41           17                1.18 \[0.71--1.97\]      0,51          0.82 \[0.40--1.67\]   0,58         2.0 \[0.59--6.46\]    0,27         0.99 \[0.50--1.94\]   0,97          1,26   0,53
             rs3020450   177            163         44                 353            237          59                0.78 \[0.64--0.94\]      **0,01**      0.73 \[0.56--0.95\]   **0,02**     0.67 \[0.44--1.03\]   0,07         0.72 \[0.56--0.92\]   **0,01**      0,8    **0,01**
             Women       147            139         41                 288            202          42                0.72 \[0.58--0.89\]      **0,002**     0.74 \[0.55--1.00\]   **0,05**     0.52 \[0.33--0.84\]   **0,007**    0.69 \[0.52--0.91\]   **0,009**     0,73   **0,003**
             Men         30             24          3                  65             35           17                1.17 \[0.71--1.94\]      0,54          0.67 \[0.34--1.32\]   0,25         2.61 \[0.71--9.61\]   0,14         0.89 \[0.47--1.68\]   0,72          1,32   0,57
  *ESR2*     Women                                                                                                                                                                                                                                                           
             rs1152582   54             171         110                127            274          161               0.80 \[0.66--0.98\]      **0,03**      0.68 \[0.47--1.00\]   **0,04**     0.62 \[0.42--0.93\]   **0,01**     0.66 \[0.46--0.94\]   **0,02**      0,8    **0,03**
             rs1271572   59             172         104                130            281          151               0.82 \[0.68--1.00\]      **0,05**      0.74 \[0.52--1.06\]   0,1          0.66 \[0.44--1.00\]   **0,04**     0.71 \[0.50--1.00\]   **0,05**      0,82   **0,04**
             rs1269056   53             175         107                127            275          158               0.81 \[0.66--0.98\]      **0,03**      0.66 \[0.45--0.95\]   **0,03**     0.62 \[0.41--0.92\]   **0,02**     0.64 \[0.45--0.91\]   **0,01**      0,8    **0,03**
  *ESR2*     Men                                                                                                                                                                                                                                                             
             rs4986938   4              30          30                 20             59           45                0.64 \[0.40--1.00\]      **0,05**      0.39 \[0.12--1.26\]   0,11         0.30 \[0.09--0.96\]   **0,04**     0.35 \[0.11--1.06\]   **0,05**      0,6    **0,05**
  Sample 2                                                                                                                                                                                                                                                                   
  *ESR2*     rs3020450   326            245         41                 410            332          60                1.08 \[0.91--1.27\]      0,39          1.08 \[0.86--1.34\]   0,51         1.16 \[0.76--1.78\]   0,48         1.09 \[0.88--1.34\]   0,42          1.08   0,38
             Women       273            216         35                 346            282          53                1.06 \[0.89--1.27\]      0,42          1.03 \[0.81--1.31\]   0,81         1.20 \[0.76--1.88\]   0,44         1.05 \[0.84--1.32\]   0,65          1.07   0,51
             Men         53             29          6                  64             50           7                 1.18 \[0.75--1.86\]      0,46          1.42 \[0.80--2.56\]   0,23         0.97 \[0.31--3.05\]   0,95         1.35 \[0.77--2.35\]   0,29          1.11   0,46
             rs7154455   318            248         46                 399            341          63                1.06 \[0.90--1.26\]      0,45          1.10 \[0.88--1.37\]   0,42         1.09 \[0.73--1.64\]   0,67         1.09 \[0.89--1.35\]   0,40          1.06   0,44
             Women       268            216         40                 337            287          57                1.06 \[0.89--1.27\]      0,52          1.06 \[0.83--1.34\]   0,65         1.13 \[0.73--1.75\]   0,57         1.07 \[0.85--1.34\]   0,57          1.06   0,52
             Men         50             32          6                  62             54           6                 1.11 \[0.71--1.73\]      0,64          1.36 \[0.77--2.42\]   0,29         0.81 \[0.24--2.65\]   0,72         1.27 \[0.73--2.21\]   0,74          1.05   0,63

a\) Shown are SNPs with P value \< 0.05 in at least one analysis.

b\) 1 and 2 represent the two alleles of each SNP.

c\) OR (95% confidence interval)

In sample 1, no *ESR1*haplotype was associated with obesity, Table [3](#T3){ref-type="table"}. One common *ESR2*haplotype, TCCC (frequency 29%) at SNPs rs3020450-rs1271572-rs1887994-rs7159462 was associated with obesity, nominal P value 0.024, Table [3](#T3){ref-type="table"}. TCCC was captured by SNP rs3020450. rs3020450 was genotyped in sample 2, where we were unable to confirm the association observed in sample 1.

Relation of ESR1 SNPs and mRNA levels to adipocyte lipolysis and lipogenesis phenotypes
---------------------------------------------------------------------------------------

In 122 women with a large variation in BMI, part of sample 3, there was an inverse correlation between *ESR1*mRNA levels in abdominal sc adipose tissue and adipocyte basal lipolysis as well as responsiveness to noradrenaline and more selective adrenoceptor agonists, Figure [3](#F3){ref-type="fig"}. In multiple regression, including BMI, age, and *ESR1*mRNA levels as independent variables, *ESR1*levels were an independent factor regulating basal lipolysis (P = 0.018), as well as responsiveness to noradrenaline (P = 0.013), Table [5](#T5){ref-type="table"}. Association between *ESR1*mRNA levels and lipolytic responsiveness was stronger for the α2-adrenoceptor selective agonist clonidine (P = 0.009), than for the non-selective β-adrenoceptor agonist isoprenaline (P = 0.045), Table [5](#T5){ref-type="table"}. There was no association between *ESR1*mRNA levels and sensitivity of lipolysis to adrenoceptor agonists, nor between *ESR1*mRNA levels and measures of lipogenesis. We next analysed *ESR1*SNPs for impact on adipocyte lipolysis and lipogenesis in the 204 obese women of sample 3, for which these phenotypes had been investigated. No SNP was associated with basal lipolysis (results not shown). One *ESR1*SNP, rs532010, was associated with lipolytic sensitivity to noradrenaline, nominal P value 0.012, Table [6](#T6){ref-type="table"}. Another *ESR1*SNP, rs1884051, was associated with responsiveness to the non-selective beta-adrenoceptor agonist isoprenaline, nominal P value 0.05. These SNP associations became non-significant after Bonferroni correction for analysis of several SNPs. No *ESR1*SNP was associated with lipogenesis (results not shown).

![*ESR1*mRNA levels in abdominal sc adipose tissue plotted against (A) basal lipolysis, response to (B) noradrenaline, (C) the non-selective β-adrenoceptor agonist isoprenaline, and (D) the α2-adrenoceptor selective agonist clonidine.](1471-2350-8-73-3){#F3}

###### 

Regression of basal lipolysis and responsiveness to adrenoceptor agonist on *ERS1*mRNA levels

                              Coefficient ± SE   Std. Coeff.   T-value   P value
  --------------------------- ------------------ ------------- --------- ----------
  Basal lipolysis                                                        
  Intercept                   2.34 ± 4.54        2.34          0.51      0.61
  *ESR1*(AU)                  -3.90 ± 1.62       -0.20         -2.40     0.018
  BMI (kg/m^2^)               0.44 ± 0.10        0.39          4.61      \<0.0001
  Age (years)                 -0.14 ± 0.08       -0.15         -1.86     .065
  Response to noradrenaline                                              
  Intercept                   13.84 ± 6.40       13.84         2.16      .033
  *ESR1*(AU)                  -5.72 ± 2.26       -0.21         -2.53     .013
  BMI (kg/m^2^)               0.58 ± 0.13        0.37          4.38      \<0.0001
  Age (years)                 -0.22 ± 0.11       -.174         -2.12     .036
  Response to isoprenaline                                               
  Intercept                   15.44 ± 8.72       15.44         1.77      0.079
  *ESR1*(AU)                  -6.31 ± 3.11       -0.18         -2.03     0.045
  BMI (kg/m^2^)               0.78 ± 0.18        0.37          4.28      \<.0001
  Age (years)                 -0.16 ± 0.14       -0.10         -1.14     0.26
  Response to clonidine                                                  
  Intercept                   0.99 ± 0.92        0.99          1.08      0.28
  *ESR1*(AU)                  -0.87 ± 0.33       -0.23         -2.65     0.0091
  BMI (kg/m^2^)               0.07 ± 0.02        0.31          3.57      0.0005
  Age (years)                 -0.02 ± 0.02       -0.08         -1.00     0.32

###### 

Association between *ESR1*SNPs and lipolysis and lipogenesis phenotypes^a^

                                            Source      Sum of Squares   F Ratio   Prob \> F
  ----------------------------------------- ----------- ---------------- --------- -----------
  Noradrenaline pD2, lipolysis ^b^                                                 
  *ESR1*                                    rs532010    0.045            4.51      0.012
  Response to Isoprenaline, lipolysis ^c^                                          
  *ESR1*                                    rs1884051   0.219            3.02      0.050

a\) For quantitative analysis of lipolysis and lipogenesis, logarithm transformed phenotypes were used as independent quantitative variables in linear regression models. Genotypes were indicated as character (nominal) with three levels, two alternative homozygous and heterozygous.

b\) The concentration (log mol/l) of hormone or agonist causing half maximum effect was determined using logistic conversion of each concentration response curve. This value was converted to its negative form (pD~2~), which reflects hormone sensitivity.

c\) Lipolysis is expressed as mmol of glycerol/2 h/10^7^cells.

Discussion
==========

Estrogen signalling has been implicated in regulation of human adiposity \[[@B4]\]. There is evidence that *ESR1*acts in fat cells, whereas *ESR2*mediates the effects of estrogen on food intake \[[@B7],[@B9]\]. We here report that *ESR1*mRNA levels in adipose tissue were inversely correlated with basal lipolysis and adrenoceptor responsiveness in obese women. In sample 1, two *ESR2*SNPs were associated with obesity with nominal P value \< 0.01. However, these associations were not confirmed in sample 2. No *ESR1*SNP displayed allelic association with obesity or lipolysis.

Although no *ESR1*SNP displayed allelic association with obesity, we cannot completely exclude an impact of *ESR1*alleles on female obesity since genotyped SNPs failed to capture a few common haplotypes in the region of the *ESR1*gene.

Two *ESR2*SNPs, rs7154455 and rs3020450 were associated with obesity with nominal P value \< 0.01. The call rate for rs7154455 was only 83% adding some uncertainty to this association. rs7154455 and rs3020450 were genotyped in sample 2. In sample 2, as well as in pooled analysis of sample 1 and 2, no association with obesity was observed. This suggests that the allelic association of the two *ESR2*SNPs in sample 1 was spurious. However, since recruitment criteria for sample 2 were based on less stringent definitions of obesity and leanness, and included subjects with metabolic complications of obesity, we cannot exclude that the *ESR2*SNPs have a modest impact on more extreme forms of uncomplicated obesity such as in sample 1. In addition, this study was not designed to study potential gene-environment interactions. This is particularly important for ESR2, which has been implicated in mediating the effects of estrogen on food intake. Furthermore, our cohort of men was too small to exclude a male-specific impact of *ESR1*and *ESR2*on obesity. This might explain the difference between our results and the association of *ESR1*and male obesity previously reported \[[@B14]\].

We have reported before that *ESR1*rs2234693 and rs9340799 are not associated with obesity in a cohort of Swedish women partially overlapping with the cohort studied in this project \[[@B16]\]. We therefore did not genotype rs2234693 and rs9340799 in this study. *ESR1*rs1801132, reported to be associated with BMI in men in the Framingham Heart Study \[[@B14]\], is according to the Caucasian HAPMAP data on the same haplotype as rs9397456, which was genotyped in this project. We did not genotype the three *ESR1*SNP reported to be associated with BMI in African Americans \[[@B17]\]; however the reported BMI associated SNP rs6902771 is according to HAPMAP on the same haplotype as rs2234693, which we genotyped. We genotyped rs1709183, but not rs2431260, reported to be associated with T2D \[[@B18]\]. Finally, we genotyped rs928554 and rs4986938, but not rs1256049, implicated in eating disorders \[[@B19],[@B20]\]. SNPs genotyped in our present project, that previously have been associated with obesity related and eating disorders, were not associated with obesity in the present project.

Human obesity is associated with increased rate of basal lipolysis in all fat depots and lipolytic resistance to catecholamines in sc fat \[[@B39]\]. Our finding that *ESR1*mRNA levels in adipose tissue are inversely correlated with rate of basal lipolysis might suggest that low adipose tissue *ESR1*levels, as observed in obesity \[[@B16]\], increases basal lipolysis. In addition, the inverse correlation between *ESR1*mRNA levels and lipolytic responsiveness to catecholamines implies that low adipose tissue *ESR1*levels among obese counteracts catecholamine resistance in sc fat cells of obese women. Catecholamine resistance among obese is specific to sc fat \[[@B39]\]. Attenuation of lipolytic catecholamine resistance may explain why low estrogen signalling is associated with fat redistribution with loss of sc and gain of visceral fat \[[@B2]\]. In our analyses, there was no evidence for a genetic impact of *ESR1*on lipolysis or lipogenesis.

Conclusion
==========

Common *ESR1*gene alleles are unlikely to contribute to obesity in women, whereas a minor importance of *ESR2*on severe obesity cannot be excluded. The male subset in our sample was too small to exclude that *ESRs*have an impact on obesity in men. Low *ESR1*mRNA levels in adipose tissue may counteract catecholamine resistance in fat cells of obese women hereby contributing to loss of sc and gain of visceral fat \[[@B39]\]. In our analysis of obese women there was no evidence for a genetic impact of *ESR1*on lipolysis or lipogenesis. In future research, it will be important to investigate if there are interactions between ESR2 gene alleles and environmental factors such as food intake.
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